TORONTO, Oct. 20, 2011 /CNW/ - Patheon, Inc. (TSX: PTI), a global
provider of drug development and manufacturing services to the
international pharmaceutical industry announced today that Boehringer
Ingelheim, a leading globally operating pharmaceutical corporation, has
awarded it two projects with combined revenue of more than $18 million
over a three year period of time. The projects are both fixed-dose
combination drugs in development for the treatment of the growing
population of type II diabetics.
In commenting on the announcement, Mark Kontny, Patheon's President of
Pharmaceutical Development Services and Chief Scientific Officer said,
"I am very gratified that Boehringer Ingelheim recognizes our expertise
in formulating, scaling and successfully launching complex formulations
such as these molecules. It is this kind of support and recognition
that has enabled us to develop our market leading position in
pharmaceutical development services. "
Patheon Inc. (TSX: PTI) is a leading global provider of contract
development and manufacturing services to the global pharmaceutical
industry. The company provides the highest quality products and
services to approximately 300 of the world's leading pharmaceutical and
biotechnology companies. Its comprehensive range of fully integrated
Pharmaceutical Development Services includes pre-formulation,
formulation, analytical development, clinical manufacturing, scale-up
and commercialization. The company's integrated development and
manufacturing network of 10 facilities, nine development centers and
one clinical trial packaging facility across North America and Europe,
ensures that customer products can be launched with confidence anywhere
in the world.
SOURCE Patheon Inc.
For further information:
Ms. Wendy Wilson
Investor Relations and Corporate Communications
Tel: (919) 226-3313